Topic - Lilly

Related Stories

A sign for Eli Lilly & Co. sits outside their corporate headquarters in Indianapolis on April 26, 2017. A closely watched Alzheimer's drug from Eli Lilly won the backing of federal health advisers on Monday, June 10, 2024, setting the stage for the treatment's expected approval for people with mild dementia caused by the brain-robbing disease. (AP Photo/Darron Cummings, File)

Pharma giant Eli Lilly suing providers of fake meds passed off as Mounjaro, Zepbound

By Brad Matthews - The Washington Times

Rick Elskamp sits with his oldest daughter, Sheridan, and discusses the frustrations of having his 23-year-old daughter on a waiting list for 10 years for services as an intellectually disabled adult, Saturday, Jan. 27, 2024, at the Elskamps' home outside Topeka, Kan. Thousands of Kansas residents with disabilities and hundreds of thousands across the U.S. are on waiting lists for services. (AP Photo/John Hanna)

States offer services for disabled kids, then make their families wait 10 years for them

By John Hanna - Associated Press

President Biden speaks at the "Sunday Lunch" event at the Brookland Baptist Banquet Center, part of the Brookland Baptist Church, in West Columbia, S.C., on Sunday, Jan. 28, 2024. (AP Photo/Jacquelyn Martin)

Biden is marking the 15th anniversary of landmark pay equity law with steps to help federal workers

By Darlene Superville - Associated Press

A sign for Eli Lilly & Co. sits outside their corporate headquarters in Indianapolis on April 26, 2017. The company said Wednesday, May 3, 2023, that its experimental Alzheimer’s drug appeared to slow worsening of the mind-robbing disease in a large study. (AP Photo/Darron Cummings, File)

Eli Lilly says experimental drug slows Alzheimer’s worsening

Associated Press

This combination of photos provided by Matthew Barlow shows him in November 2022, left, and April 2023 in California. Barlow, a 48-year-old health technology executive, said he has lost more than 100 pounds since November by using the drug Mounjaro and changing his diet. (Courtesy Matthew Barlow via AP)

Powerful new obesity drug poised to upend weight loss care

By Jonel Aleccia - Associated Press

FILE - This April 26, 2017, file photo shows the Eli Lilly & Co. corporate headquarters in Indianapolis. Eli Lilly shares slipped Friday, Jan. 20, 2023, after regulators said they need to see more data on the company’s application for a quick approval of its potential Alzheimer’s disease treatment. (AP Photo/Darron Cummings, File)

Lilly shares slip as FDA seeks more Alzheimer’s drug data

Associated Press

FILE- In this April 26, 2017, file photo shows the Eli Lilly and Co. corporate headquarters in Indianapolis. Eli Lilly fell well short of Wall Street’s first-quarter expectations, Tuesday, April 27, 2021, and the drugmaker chopped the top end of its earnings forecast due to lower demand for COVID-19 treatments. (AP Photo/Darron Cummings, File)

Slipping COVID-19 treatment demand hits Eli Lilly forecast

By TOM MURPHY - Associated Press

Woman ordered to repay $46K for Portland protest damage

Associated Press

This photo provided by Eli Lilly shows the drug bamlanivimab. On Tuesday, Jan. 26, 2021, the company said that the two-antibody combo of bamlanivimab and etesevimab reduced the risk of hospitalizations or death by 70% in newly diagnosed, non-hospitalized COVID-19 patients at high risk of serious illness because of age or other health conditions. (Eli Lilly via AP)

Studies extend hopes for antibody drugs against COVID-19

By MARILYNN MARCHIONE - Associated Press

FILE - This April 26, 2017 file photo shows the Eli Lilly &amp; Co. corporate headquarters in Indianapolis. Shares of Eli Lilly jumped after the drugmaker laid out a better-than-expected revenue forecast and plans to buy a young company developing a potential Parkinson’s disease treatment. Lilly also projected on Tuesday, Dec. 15, 2020, a 2021 earnings range that brackets average Wall Street expectations. (AP Photo/Darron Cummings)

Lilly lays out 2021 expectations, gene therapy acquisition

By TOM MURPHY - Associated Press

This photo provided by Eli Lilly shows the drug bamlanivimab. On Monday, Nov. 9, 2020, the Food and Drug Administration cleared emergency use of bamlanivimab, the first antibody drug to help the immune system fight COVID-19. The drug is for people 12 and older with mild or moderate COVID-19 not requiring hospitalization. (Courtesy of Eli Lilly via AP)

US allows 1st emergency use of a COVID-19 antibody drug

By Matthew Perrone - Associated Press

FILE - This is an April 26, 2017, file photo showing Eli Lilly corporate headquarters in Indianapolis. Eli Lilly continues to back a potential COVID-19 treatment despite research showing that it may not work on hospitalized patients. The drugmaker said Tuesday, Oct. 27, 2020, that It remains confident that its drug may stop COVID from developing in other patients. (AP Photo/Darron Cummings, File)

Lilly stays confident in possible COVID drug after setback

By TOM MURPHY - Associated Press

Lilly misses profit projects as sales of diabetes drug slow

Associated Press

FILE - In this May 2020 file photo provided by Eli Lilly, a researcher tests possible COVID-19 antibodies in a laboratory in Indianapolis. On Monday, Oct. 26, 2020, U.S. government officials announced they are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalized with COVID-19 because it doesn’t seem to help. (David Morrison/Eli Lilly via AP, File)

Lilly antibody drug fails in a COVID-19 study; others go on

By MARILYNN MARCHIONE - Associated Press

2nd girl dies after 4 pulled from burning NE Indiana home

Associated Press